Literature DB >> 6448304

Suppressor cells in immunodepressed bladder and prostate cancer patients.

H W Herr.   

Abstract

Peripheral blood lymphocytes from 23 patients with bladder and prostate cancer were tested for their ability to respond in vitro to phytohemagglutinin, concanavalin A and allogeneic cells. The lymphocyte response was depressed in 15 patients (65 per cent), 13 with advanced disease, compared to peripheral blood lymphocytes from age-matched hospitalized control subjects tested on the same day. Furthermore, the hyporesponsive lymphocytes from 11 of the 15 cancer patients (73 per cent) inhibited the phytohemagglutinin, concanavalin A and mixed lymphocyte culture reactivity of normal lymphocytes in co-cultures (16 to 78 per cent suppression). In contrast, lymphocytes from control donors caused no suppression. Incubation of the patients' unseparated peripheral blood lymphocytes on plastic to remove adherent cells restored lymphocyte responsiveness and eliminated their suppressor activity. Returning the adherent cells to cultures with patients' autologous separated and normal lymphocytes recaptured the suppressive effect. Pre-incubation of the patients' lymphocytes with concanavalin A markedly enhanced their ability to suppress and induced moderate suppressor activity by normal lymphocytes. These data suggested that 1 mechanism for the depression of cell-mediated immunity seen in patients with advanced urological cancer may be owing to non-specific suppressor cells, possibly monocytes.

Entities:  

Mesh:

Year:  1980        PMID: 6448304

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  The relationship between clinical stage, natural killer activity and related immunological parameters in adenocarcinoma of the prostate.

Authors:  N Lahat; B Alexander; D R Levin; B Moskovitz
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 2.  Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer.

Authors:  P Goedegebuure; J B Mitchem; M R Porembka; M C B Tan; B A Belt; A Wang-Gillam; W E Gillanders; W G Hawkins; D C Linehan
Journal:  Curr Cancer Drug Targets       Date:  2011-07       Impact factor: 3.428

3.  Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer.

Authors:  Stanimir Vuk-Pavlović; Peggy A Bulur; Yi Lin; Rui Qin; Carol L Szumlanski; Xinghua Zhao; Allan B Dietz
Journal:  Prostate       Date:  2010-03-01       Impact factor: 4.104

Review 4.  Rebuilding immunity in cancer patients.

Authors:  Stanimir Vuk-Pavlovic
Journal:  Blood Cells Mol Dis       Date:  2007-09-10       Impact factor: 3.039

5.  Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer.

Authors:  Jennifer D Wu; Lily M Higgins; Alexander Steinle; David Cosman; Kathy Haugk; Stephen R Plymate
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

6.  Inhibition of lymphocyte response by prostaglandin-producing suppressor cells in patients with melanoma.

Authors:  J L Murray; G M Kollmorgen
Journal:  J Clin Immunol       Date:  1983-07       Impact factor: 8.317

7.  Role of the spleen on immunosuppression in esophageal and gastric cancer.

Authors:  T Toge; A Kameda; H Yamada; Y Seto; K Aratani; T Fujita; T Hattori
Journal:  Jpn J Surg       Date:  1986-09

8.  Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins.

Authors:  G Pirtskhalaishvili; G V Shurin; C Esche; Q Cai; R R Salup; S N Bykovskaia; M T Lotze; M R Shurin
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.